Imipramine (CAS 50-49-7) – TCA Antidepressant Mood Regulator API

Imipramine (CAS 50-49-7) is a high-purity pharmaceutical API classified as a classic tricyclic antidepressant (TCA), featuring a dibenzazepine molecular structure with dual mechanisms of action. It selectively inhibits the reuptake of norepinephrine and serotonin in the central nervous system, elevating synaptic neurotransmitter levels to alleviate depressive symptoms, while also exerting mild anxiolytic effects to improve emotional regulation. Unlike newer antidepressants, it demonstrates proven efficacy for severe depression and enuresis in children, with a well-established safety profile for long-term use.

Presented as a white to off-white crystalline powder with good oral bioavailability and stability, it is adaptable to various oral dosage forms. It caters to the core needs of psychiatric drug manufacturers, antidepressant formulation developers, and pediatric medicine suppliers. Widely applied in treating major depressive disorder, panic disorder, and childhood enuresis, it aligns with demand for reliable, multi-indication antidepressant raw materials. Produced under strict GMP standards, each batch undergoes rigorous purity, dissolution rate, and potency testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use.